PE20011374A1 - 4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS - Google Patents

4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS

Info

Publication number
PE20011374A1
PE20011374A1 PE2001000566A PE2001000566A PE20011374A1 PE 20011374 A1 PE20011374 A1 PE 20011374A1 PE 2001000566 A PE2001000566 A PE 2001000566A PE 2001000566 A PE2001000566 A PE 2001000566A PE 20011374 A1 PE20011374 A1 PE 20011374A1
Authority
PE
Peru
Prior art keywords
alkyl
azepan
amino
ona
het
Prior art date
Application number
PE2001000566A
Other languages
Spanish (es)
Inventor
Maxwell D Cummings
Marquis
Dennin S Yamashita
Scott K Thompson
Daniel F Veber
Yu Ru
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20011374A1 publication Critical patent/PE20011374A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE 4-AMINO-AZEPAN-3-ONA DE FORMULA IA DONDE R1 ES R4(R')NCHR3-CO-; R4(R')NC(R3)(R'''')-CO-, GRUPO a; R2 ES ALQUILO C1-C6, Ar-ALQUILO C0-C6, HET-ALQUILO C0-C6, R9C(O)- ENTRE OTROS; R3 ES ALQUILO C1-C6; R4 ES R5C(O)-; R5 ES HET-ALQUILO C0-C6 TAL COMO PIPERIDINIL-ETILO, BENZO[1,3]DIOXOLILO, FURANILO, ENTRE OTROS; R9 ES ALQUILO C1-C6, CICLOALQUIL C3-C6-ALQUILO C0-C6, Ar-ALQUILO C0-C6, ENTRE OTROS; R' , R'', R''' SON H; R'''' ES ALQUILO C1-C6, CICLOALQUILO C3-C6-ALQUILO C0-C6, ALQUENILO C2-C6, ENTRE OTROS; n ES 1 A 5. SON COMPUESTOS PREFERIDOS {(S)-1-[(3-FLUORO-BENCENOSULFONIL)-3-OXO-AZEPAN-4-ILCARBAMOIL]-3-METIL-1-BUTIL}-AMIDA DE ACIDO BENZOFURAN-2-CARBOXILICO; 3-[OXO-1-(PIRIDINA-2-SULFONIL)-AZEPAN-4-OL]AMIDA DE ACIDO (S)-4-METIL-2-[3-PIPERIDIN-1-ILPROPANOILAMINO)-PENTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. EL COMPUESTO I ES UN INHIBIDOR DE CISTEINA O SERINA PROTEASA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES CON PERDIDA OSEA, PERIODONTITIS, GINGIVITIS, OSTEOARTRITIS, ARTRITIS REUMATOIDE, ESQUISTOSOMIASIS, MALARIAREFERS TO 4-AMINO-AZEPAN-3-ONA COMPOUNDS OF FORMULA IA WHERE R1 IS R4 (R ') NCHR3-CO-; R4 (R ') NC (R3) (R' '' ') - CO-, GROUP a; R2 IS C1-C6 ALKYL, Ar-C0-C6 ALKYL, HET-C0-C6 ALKYL, R9C (O) - AMONG OTHERS; R3 IS C1-C6 ALKYL; R4 IS R5C (O) -; R5 IS C0-C6 HET-ALKYL SUCH AS PIPERIDINYL-ETHYL, BENZO [1,3] DIOXOLYL, FURANIL, AMONG OTHERS; R9 IS C1-C6 ALKYL, C3-C6 CYCLOALKYL-C0-C6 ALKYL, Ar-C0-C6 ALKYL, AMONG OTHERS; R ', R' ', R' '' ARE H; R '' '' IS C1-C6 ALKYL, C3-C6 CYCLOALKYL-C0-C6 ALKYL, C2-C6 ALKYL, AMONG OTHERS; n IS 1 TO 5. ARE PREFERRED COMPOUNDS {(S) -1 - [(3-FLUORO-BENZENOSULFONIL) -3-OXO-AZEPAN-4-ILCARBAMOIL] -3-METHYL-1-BUTYL}-BENZOFURAN ACID AMIDE- 2-CARBOXYL; 3- [OXO-1- (PYRIDINE-2-SULFONIL) -AZEPAN-4-OL] AMIDE OF ACID (S) -4-METHYL-2- [3-PIPERIDIN-1-ILPROPANOYLAMINO) -PENTANOICO, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. COMPOUND I IS AN INHIBITOR OF CYSTINE OR SERINE PROTEASE AND MAY BE USEFUL FOR THE TREATMENT OF DISEASES WITH BONE LOSS, PERIODONTITIS, GINGIVITIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SCHISTOSOMIASIS, MALARIA

PE2001000566A 2000-06-14 2001-06-14 4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS PE20011374A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59384500A 2000-06-14 2000-06-14

Publications (1)

Publication Number Publication Date
PE20011374A1 true PE20011374A1 (en) 2002-04-07

Family

ID=24376433

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000566A PE20011374A1 (en) 2000-06-14 2001-06-14 4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS

Country Status (25)

Country Link
EP (1) EP1307204A4 (en)
JP (1) JP2004503502A (en)
KR (1) KR20030008220A (en)
CN (1) CN1444481A (en)
AP (1) AP2002002671A0 (en)
AR (1) AR032622A1 (en)
AU (1) AU2001268407A1 (en)
BG (1) BG107327A (en)
BR (1) BR0111693A (en)
CA (1) CA2412353A1 (en)
CZ (1) CZ20024086A3 (en)
EA (1) EA200300018A1 (en)
EC (1) ECSP024388A (en)
HU (1) HUP0301231A2 (en)
IL (1) IL153421A0 (en)
MA (1) MA25758A1 (en)
MX (1) MXPA02012442A (en)
NO (1) NO20025786L (en)
NZ (1) NZ522965A (en)
OA (1) OA12288A (en)
PE (1) PE20011374A1 (en)
PL (1) PL360508A1 (en)
SK (1) SK17592002A3 (en)
WO (1) WO2001095911A1 (en)
ZA (1) ZA200209808B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034158A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034159A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
PL366232A1 (en) * 2000-11-22 2005-01-24 Smithkline Beecham Corporation Protease inhibitors
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
PL204456B1 (en) 2001-02-20 2010-01-29 Chugai Pharmaceutical Co Ltd Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
AU2002342682A1 (en) * 2001-05-17 2002-11-25 Smithkline Beecham Corporation Protease inhibitors
ES2309563T3 (en) 2003-08-01 2008-12-16 Chugai Seiyaku Kabushiki Kaisha PIPERIDINE COMPOUNDS USED AS INHIBITORS FROM MALONIL COENZIMA TO DESCARBOXYLASE.
JP4727578B2 (en) 2003-08-01 2011-07-20 中外製薬株式会社 Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
ES2378418T3 (en) 2003-08-01 2012-04-12 Chugai Seiyaku Kabushiki Kaisha Cyanoguanidine-based azol compounds useful as malonyl-coadescarboxylase inhibitors
EP2240491B1 (en) 2008-01-09 2015-07-15 Amura Therapeutics Limited TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES
CN103275070A (en) * 2013-05-10 2013-09-04 郑彪 Tetracyclic compound for adjusting proliferation of mononuclear cells and application of tetracyclic compound
US9427441B2 (en) 2014-02-19 2016-08-30 Indiana University Research And Technology Corporation Targeting primary cilia to treat glaucoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (en) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.
BR9916488A (en) * 1998-12-23 2001-10-09 Smithkline Beecham Corp Protease inhibitors
WO2001034565A2 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034158A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2004509083A (en) * 2000-09-01 2004-03-25 スミスクライン・ビーチャム・コーポレイション Method of treatment
PL366232A1 (en) * 2000-11-22 2005-01-24 Smithkline Beecham Corporation Protease inhibitors
AU2002342682A1 (en) * 2001-05-17 2002-11-25 Smithkline Beecham Corporation Protease inhibitors

Also Published As

Publication number Publication date
NO20025786L (en) 2003-02-12
ECSP024388A (en) 2003-02-06
OA12288A (en) 2003-12-12
ZA200209808B (en) 2004-07-09
EA200300018A1 (en) 2003-06-26
JP2004503502A (en) 2004-02-05
AR032622A1 (en) 2003-11-19
MA25758A1 (en) 2003-04-01
NO20025786D0 (en) 2002-12-02
EP1307204A4 (en) 2004-06-02
PL360508A1 (en) 2004-09-06
WO2001095911A1 (en) 2001-12-20
NZ522965A (en) 2004-06-25
HUP0301231A2 (en) 2003-08-28
AU2001268407A1 (en) 2001-12-24
CZ20024086A3 (en) 2003-05-14
BG107327A (en) 2003-07-31
IL153421A0 (en) 2003-07-06
AP2002002671A0 (en) 2002-12-31
KR20030008220A (en) 2003-01-24
BR0111693A (en) 2004-04-06
EP1307204A1 (en) 2003-05-07
SK17592002A3 (en) 2003-05-02
MXPA02012442A (en) 2003-04-25
CA2412353A1 (en) 2001-12-20
CN1444481A (en) 2003-09-24

Similar Documents

Publication Publication Date Title
PE20011233A1 (en) AMINOAZEPAN-3-ONA ALKYL COMPOUNDS AS PROTEASE INHIBITORS
PE20001340A1 (en) 4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS
PE20011374A1 (en) 4-AMINO-AZEPAN-3-ONA AS PROTEASE INHIBITORS
PE20010984A1 (en) NITRILE DERIVATIVES AS CATEPSIN K INHIBITORS
PE110899A1 (en) DERIVATIVES OF ARILOXIARILSULFONILAMINO HIDROXAMICOS ACIDS
PE71599A1 (en) PROTEASE INHIBITORS
PE20081583A1 (en) ANTIBACTERIAL AGENTS DERIVED FROM CARBONYLAMINE COMPOUNDS
AU4688301A (en) Stabilized pharmaceutical compositions containing calcium channel blockers
YU34896A (en) Substituted n-(indole-2-carbonyl)-glycinamides, intermediates thereof and pharmaceutical compositions
PE20021005A1 (en) QUINAZOLINES AS INHIBITORS OF MMP-13
PE128799A1 (en) ANTIMICROBIAL QUINOLINS AND THEIR COMPOSITIONS
PE20031012A1 (en) HEPATITIS C INHIBITOR COMPOUND
PE20020786A1 (en) DERIVATIVES OF AZAINDOL ANTIVIRAL
PE20021014A1 (en) GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD
DE69615058D1 (en) METALLOPROTEINASE INHIBITORS
PE20050012A1 (en) BENZOPYRANE COMPOUNDS AS CYCLOOXYGENASE-2 INHIBITORS
PE20090548A1 (en) AZA-BICYCLOHEXANE COMPOUNDS AS THROMBIN INHIBITORS
AR008621A1 (en) A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION
PE64398A1 (en) AZETIDINONE DERIVATIVES
PE20050312A1 (en) PEPTIDYL COMPOUNDS AS CATEPSIN S INHIBITORS
PE20050160A1 (en) 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE
PE20001486A1 (en) ANNULAR ETEREO COMPOUNDS FROM 7 TO 14 MEMBERS AS PROTEASE INHIBITORS
PE20001241A1 (en) CERTAIN SUBSTITUTED CAPROLACTAMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE TREATMENT OF TUMORS
HUT39966A (en) Insecticides containing as active substance acetilized sacharin-derivatives and process for production of this active substance
PE20001355A1 (en) 1,3-DIAMINE-KETONES AS PROTEASE INHIBITORS

Legal Events

Date Code Title Description
FC Refusal